Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NucleomaxX or Tenofovir switch for HIV lipoatrophy
NCT00119379Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2005
- Primary completion
- Oct 2008
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of uridine triacetate in HIV-associated lipoatrophy, sponsored by National Institute of Allergy and Infectious Diseases. Started Apr 2005; status: completed.
02
Drugs
uridine triacetate
03
Conditions
HIV-associated lipoatrophy
Beyond the preview
Go deeper on NCT00119379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00119379.